


Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)		Docket Number 378332000900	Application Number 09/183,375
		Applicant	J. SZEBENI et al.
		Filing Date October 30, 1998	Group Art Unit 1615
		Mailing Date August 31, 2000	



### U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	07/31/1997	WO 97/26862	PCT			
	2.	02/23/1994	EP 0 584 001 A1	EPO			

### OTHER DOCUMENTS

*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	3.	Decorti et al., 1996 "Effect of Paclitaxel and Cremophor EL on Mast Cell Histamine Secretion and Their Interaction with Adriamycin" Anticancer Research 16: 317-320
	4.	Eisenhauer et al., 1994 "European-Canadian Randomized Trial of Paclitaxel in Relapsed Ovarian Cancer: High-Dose Versus Low-Dose and Long Versus Short Infusion" Journal of Clinical Oncology, 12(12): 2654-2666
	5.	Essayan et al., 1996 "Successful Parenteral Desensitization to Paclitaxel" Journal of Allergy Clinical Immunology, 97(1): 42-46
	6.	Hammerschmidt et al., 1980 "Association of Complement Activation and Elevated Plasma-C5a With Adult Respiratory Distress Syndrome" The Lancet, May 3, 1980: 947-949
	7.	Marceau et al., 1987 "Effects of the Anaphylatoxins on Circulation" Immunopharmacology, 14: 67-84
	8.	Michaud, 1997 "Methods for Preventing Reactions Secondary to Cremophor EL" Annals of Pharmacotherapy, 31(11): 1402-1404
	9.	O'Brien et al., 1992 "Allergic Reactions to Cytotoxic Drugs - an Update" Annals of Oncology, 3: 605-610
	10.	Szebeni, 1998 "The Interaction of Liposomes with the Complement System" Critical Reviews in Therapeutic Drug Carrier Systems, 15(1): 57-88
	11.	Szebeni et al, 1998 "Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: an In Vitro Study" Journal of the National Cancer Institute, 90(4): 300-306

EXAMINER: (examiner) <i>[Signature]</i>	DATE CONSIDERED: <i>3/8/1</i>
---	-------------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)		Docket Number 378332000900	Application Number 09/183,375
		Applicant	J. SZEBENI et al.
		Filing Date October 30, 1998	Group Art Unit 1615
		Mailing Date August 31, 2000	

✓	12.	Szebeni et al., 1997 "Complement Activation In Vitro by the Red Cell Substitute, Liposome-encapsulated Hemoglobin: Mechanism of Activation and Inhibition by Soluble Complement Receptor Type 1" Transfusion, 37(2): 150-159
	13.	Szebeni et al., 1997) "Complement Activation and Thromboxane Secretion by Liposome-Encapsulated Hemoglobin in Rats In Vitro: Inhibition by Soluble Complement Receptor Type 1" Art., Cells, Blood Subs., and Immob. Biotech., 25(4): 347-355
	14.	Terwogt et al, 1997 "Alternative Formulations of Paclitaxel" Cancer Treatment Reviews 23(2): 87-95
	15.	Wassef et al., 1989 "Anaphylactoid Reactions Mediated by Autoantibodies to Cholesterol in Miniature Pigs" The Journal of Immunology 143(8): 2990-2995
✓	16.	Weiss et al., 1990 "Hypersensitivity Reactions From Taxol" Journal of Clinical Oncology, 8(7): 1263-1268

EXAMINER: <i>Kesler</i>	DATE CONSIDERED: 3   0
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	